Weight-loss drugs work, but here's when the weight starts to return
The research looked at data from 11 previously conducted clinical trials involving nearly 2,500 participants. Of these, six studies focused on semaglutide, the active ingredient in popular drugs like Ozempic and Wegovy.While these drugs helped participants lose weight during treatment, the benefits faded after the medications were stopped.At 4 weeks after stopping the drugs, there was no prominent change in weight compared to those not on medication.By 8 weeks, participants began regaining weight, an average of 1.5 kg, compared to the control group.At 12 weeks, the regain continued, an average of 1.76 kg.By 20 weeks, people had regained 2.5 kg on average.The weight regain was most noticeable in patients who had been on GLP-1 receptor agonist drugs, such as semaglutide and tirzepatide, the class of drugs that includes Wegovy and Mounjaro.The researchers, from Peking University People's Hospital, China, say this rebound effect could happen because once the drugs are stopped, the body's appetite and metabolism tend to return to their original state.Many of these medications work by mimicking hormones that regulate hunger and fullness, effects that don't last once the drug is out of the system.Besides this, the study found that even participants who followed lifestyle changes (like improved diet and exercise) during treatment still experienced weight regain after stopping medication.WHAT THIS MEANS FOR LONG-TERM WEIGHT MANAGEMENTCurrently, six drugs are approved for obesity treatment in adults: orlistat, naltrexone-bupropion, semaglutide, liraglutide, tirzepatide and phentermine-topiramate.While these medicines are often effective for short-term weight loss, they are not a permanent solution by themselves.The findings support the idea that anti-obesity medications should be seen as part of a broader, long-term strategy, which includes lifestyle changes, behavioural therapy, and even bariatric surgery when necessary.Doctors and patients alike should focus on building sustainable habits such as nutrition, movement, and stress management, alongside any medical treatment.As researchers put it, more long-term studies are needed to fully understand how to maintain weight loss after stopping these drugs.- EndsMust Watch
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
From 189 to 103 kg: How a 25-year-old designed his own diet and lost 86 kilos
This is not just a story of weight loss, it's a story of survival, self-respect, and reclaiming life from the edge. At 25, Aditya Subramanian reached 189.6 kilos, battling health issues, emotional isolation, and the aftermath of a pandemic. Tired of too many ads? go ad free now But instead of giving up, a decision was made, not to fit into a certain size, but to find a future again. What follows is an honest, deeply human story of a transformation that was much needed. 'I wasn't just heavy, I felt invisible, broken, and tired of pretending I was okay' At 189.6 kilos, everything felt like a struggle. My bed literally gave up on me. Twice. I needed machines to breathe at night. Blood pressure? Off the charts. Fatty liver? Check. Prediabetic? Almost there. At just 25, my body was screaming for help, but my mind was too exhausted to listen. COVID didn't just change the world, it changed my relationship with food, my body, my emotions. I ate because I was anxious. I ate because I was lonely. And no matter how much I ate, I never felt full. Hunger wasn't physical anymore, it had become emotional. I even tried Ozempic for a while. It didn't help, and honestly, as a student abroad, I couldn't afford it. What hurt the most? The silence in my parents' eyes when they saw me at graduation. They didn't say a word, but it broke me. That look stayed with me longer than any diet ever did. It was the moment I knew, I had to do something. Not for them. Not for the world. But for me. 'Surgery was a tool, not a shortcut' I came back to India and made a decision that many still hesitate to talk about openly, I went for bariatric surgery. It wasn't a magic fix. It wasn't about losing weight fast. It was about surviving. It was about wanting to live without machines, without pain, without shame. Tired of too many ads? go ad free now But the surgery was just the beginning. The diet plan I was given post-op didn't work for me. It was too basic, too rigid, and didn't consider how I lived, especially as someone moving back and forth between India and Australia. Most of the products weren't available where I lived. It felt like a one-size-fits-all plan for a life that was anything but standard. So, I started building my own blueprint. I asked questions, lots of them. I spoke with doctors across countries, reached out to real people who had gone through this, and figured out what my body needed, not what the textbook said it did. I experimented with food, timing, and nutrients until I found balance. I built my own rhythm. 'I didn't punish my body, I partnered with it' There's this myth that weight loss has to be brutal. That it should be filled with shame, restriction, and endless hustle. I didn't want to lose weight out of hate. I wanted to heal out of care. I ditched the harsh rules. No starving. No extreme workouts. I focused on nourishment. I made movement gentle and joyful, walks, stretches, anything that felt doable on bad days. And when I couldn't show up at 100%, I showed up at 20%. But I showed up. (Representational image: iStock) And slowly, my body responded. No more CPAP. No more medications. My liver started healing. My blood sugar stabilised. It felt like I had been underwater for years, and suddenly, I could breathe again. 'Progress didn't come fast, it came real' People love dramatic before-and-after stories. But mine wasn't a three-month makeover. It was three years of showing up even when no one else was watching. From 189 to 103 kilos, 86 kilos gone. But what I gained was so much more. Yes, I look different. But more importantly, I feel different. I trust myself now. I'm not afraid of food. I'm not afraid of relapsing. Because I didn't sprint to this place. I walked here. One stubborn, hopeful, deliberate step at a time. 'This isn't just my story, it's a mirror for many who feel unseen' Back in Australia now, life isn't perfect. There are still bills to pay. Emotions to manage. Skin I'm planning to have removed. But there's one thing I hold close, I did this my way. With honesty. With heart. With no shortcuts. And I want to say this, especially for people from India or the diaspora: weight struggles are not just about food or fitness. They're about loneliness, about silence, about systems that don't always listen to our needs. We don't talk about it enough. We shame people instead of supporting them. So here I am. Sharing not to impress, but to connect. If this story makes even one person feel seen, feel less alone, feel like healing is possible, then every difficult day, every hard choice, every quiet win was worth it. If you have a weight loss story to share, send it to us at These views are not generic in nature. Weight loss results vary for individuals and the views shared in this article offer no guarantee of specific results. The content is not intended in any way as a substitute for professional advice. Boney Kapoor Drops 26 Kg Without Gym: Emotional Journey Behind the Transformation
India Today
9 hours ago
- India Today
What are GLP-1 drugs, why are they used for weight loss?
What are GLP-1 drugs, why are they used for weight loss? Credit: Getty Images GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which regulates blood sugar and appetite. What are GLP-1 drugs? These drugs were first developed to manage type 2 diabetes by helping the pancreas release insulin after meals. Originally for diabetes GLP-1 drugs slow down digestion, reduce hunger, and make people feel full faster, leading to reduced calorie intake. How they aid weight loss Popular names include Semaglutide (sold as Ozempic, Wegovy) and Tirzepatide (sold as Mounjaro, Zepbound). Common GLP-1 brands Most GLP-1 drugs are taken as weekly or daily injections, though oral versions like Rybelsus also exist. How they're taken Clinical trials show people can lose 10–20% of body weight when combined with diet and lifestyle changes. Weight loss results Common side effects include nausea, vomiting, constipation, and, in rare cases, pancreatitis or gallstones. Side effects to know GLP-1s are not advised for those with certain thyroid cancers or a family history of such conditions. Not for everyone Doctors emphasise these are not magic bullets—they work best with medical supervision, nutrition, and exercise. Part of a bigger plan
Hindustan Times
10 hours ago
- Hindustan Times
Indian firms aim to gorge on weight-loss drugs
Until recently, Indians had few safe ways of joining the global craze for weight-loss drugs. Some smuggled them into the country when returning home from abroad; others chanced it with bootlegged versions from Dubai. But in March Mounjaro, a weight-loss drug from Eli Lilly, an American pharmaceutical giant, became legally available in India. In June Wegovy, a drug from Novo Nordisk, a Danish firm, followed. Demand is surging. Though Indians are on average slimmer than people in most other countries, the obese population is one of the largest in the world, along with America's and China's. In Delhi, every fourth resident has Type 2 diabetes. Between 2021 and 2024 Indian sales of weight-loss drugs grew five-fold to $72m. India's market could soon grow to $1bn, predicts Jefferies, an investment bank. This may be a modest share of the $24bn in annual global sales of weight-loss drugs. But as the global market is set to rocket to $150bn in annual sales in the next decade, industry insiders see India as a juicy target. Mounjaro was an instant hit: consumption tripled from March to April, according to one industry tracker. Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper versions of an inferior first-generation injectable, liraglutide. Sun Pharma, India's biggest drugs company, hopes to launch its own jab in five years. The Indian market is especially lucrative because those who most need to lose weight are also best placed to pay up. In America, poorer people tend to be fatter. But in India obesity peaks in the most prosperous southern regions and is more common among urban than rural populations. The university-educated are more likely to be obese, too. Indeed, the real boom will come next year. That is when the patent for semaglutide, the active ingredient in Ozempic and Wegovy, expires in India. The country's generics giants, such as Cipla and Lupin, will sprint to produce knock-offs. But to cash in on home turf, Indian drug firms need to beat foreign rivals by adapting a global blockbuster to Indian realities. The first is cost. Starting at around $200 a month, Eli Lilly and Novo Nordisk's Indian offering can cost as little as a fifth of their prices in America. But a year's supply of Mounjaro or Wegovy for a single Indian can still end up being roughly equivalent to the country's GDP per person. Indian generics will slash that figure. Some analysts predict a 95% nosedive. Second, South Asians are unusually genetically predisposed to fatty-liver disease. Novo Nordisk's clinical trials suggest semaglutide might reduce it by 37%. Delivering a drug that caters to the quirks of Indian physiology gives Novo Nordisk a head start. Buckle up Finally, consider logistics. Tirzepatide and semaglutide, the active ingredients in Eli Lilly and Novo Nordisk's products, respectively, are injectables. The jabs require cold storage. That is a tough ask in a hot country with patchy logistics chains. India's Mankind Pharma is expecting trial results by the end of 2025 for what would become India's first oral weight-loss drug that could rival injectables. Both Eli Lilly and Novo Nordisk hope to enter this race with their own versions next year. Whoever makes a good weight-loss pill will prosper, especially in rural India. India is the world's biggest supplier of generic drugs, meeting about 20% of global demand. Low- and middle-income countries across Africa, Latin America and South-East Asia have some of the fastest-rising diabetes rates in the world. Dr Reddy's, an Indian pharma giant, plans to launch a generic version of Wegovy in 87 countries when the patent expires next year. The company is targeting Brazil, Turkey and other emerging markets. India also supplies nearly half the generic drugs Americans consume. For now, America levies no tariffs on them. That could change before American patents start expiring in the next decade. David Ricks, Eli Lilly's CEO, has warned that Donald Trump's tariffs could jack up the price of Indian generics. Mr Trump has spoken of slapping 200% tariffs on pharmaceuticals. On July 30th he threatened a 25% general tariff on India and an unspecified 'penalty' for its stances on trade and Russia. If Indian pharma escapes the fallout, it might yet make America skinny again. Stay on top of our India coverage by signing up to Essential India, our free weekly newsletter.
